Assembly Biosciences Book Value per Share
The Book Value per Share of Assembly Biosciences (ASMB) as of Oct 18, 2026 is 13.07 USD. In the previous year, Book Value per Share was 2.11 USD — a change of 519.78% (higher).
Get this data via API
Financial Data API
Book Value per Share
13.07USD
YoY
519.78%
Last updated:
Book Value per Share of Assembly Biosciences is 2025 13.07 USD. Book Value per Share of Assembly Biosciences was 2024 2.11 USD. It decreases by 519.78% higher compared to the previous year.
The Assembly Biosciences Book Value per Share history
3 Years
10 Years
25 Years
Max
Book Value per Share
Date
Book Value per Share
Jan 1, 2018
13.32 USD
Jan 1, 2019
17.27 USD
Jan 1, 2020
15.21 USD
Jan 1, 2021
10.68 USD
Jan 1, 2022
5.23 USD
Jan 1, 2023
2.60 USD
Jan 1, 2024
2.11 USD
Jan 1, 2025
13.07 USD
| YEAR | Book Value per Share | YoY |
|---|---|---|
| 13.07USD | +519.78% | |
| 2.11USD | -18.83% | |
| 2.60USD | -50.28% | |
| 5.23USD | -51.07% | |
| 10.68USD | -29.78% | |
| 15.21USD | -11.95% | |
| 17.27USD | +29.70% | |
| 13.32USD | +86.22% | |
| 7.15USD | +41.62% | |
| 5.05USD | -32.73% | |
| 7.51USD | +102.73% | |
| 3.70USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Assembly Biosciences Stock analysis
What does Assembly Biosciences do? Assembly Biosciences Inc is a biotechnology company based in South San Francisco, United States, specializing in the development of therapeutics for infectious diseases. The firm focuses on two primary platform programs: oral therapeutics targeting chronic hepatitis B virus (HBV) infection and oral synthetic live therapeutics designed to restore health to a dysbiotic microbiome. Its HBV program utilizes core protein allosteric modulators (CpAMs), small molecules that directly target the HBV core protein. The microbiome initiative features an integrated platform including strain identification, isolation under good manufacturing practice conditions, and the GEMICEL delivery system for targeted oral administration to the lower gastrointestinal tract. The company went public in December 2010 and employs staff dedicated to these innovative medical solutions. Assembly Biosciences is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Assembly Biosciences stock
Book Value per Share of Assembly Biosciences is 13.07 USD in 2025.
Book Value per Share of Assembly Biosciences changed from 2.11 USD to 13.07 USD, representing a 519.78% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Book Value per Share Assembly Biosciences since 2006 – with annual values, charts, and detailed analysis.
Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — Assembly Biosciences
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Assembly Biosciences
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth